CN Patent

CN111961034A — 用作ret激酶抑制剂的化合物及其应用

Assigned to Zhejiang Tongyuankang Medicine Co ltd · Expires 2020-11-20 · 5y expired

What this patent protects

本发明属于医药技术领域，具体公开了式(Ⅰ)、式(Ⅱ)、式(Ⅲ)或式(Ⅳ)所示的化合物、或其药学上可接受的盐、立体异构体、溶剂化物或前药，其中的各符号如权利要求中所定义。本发明的化合物可用作调节RET激酶活性或治疗RET相关疾病方面的药物。

USPTO Abstract

本发明属于医药技术领域，具体公开了式(Ⅰ)、式(Ⅱ)、式(Ⅲ)或式(Ⅳ)所示的化合物、或其药学上可接受的盐、立体异构体、溶剂化物或前药，其中的各符号如权利要求中所定义。本发明的化合物可用作调节RET激酶活性或治疗RET相关疾病方面的药物。

Drugs covered by this patent

Patent Metadata

Patent number
CN111961034A
Jurisdiction
CN
Classification
—
Expires
2020-11-20
Drug substance claim
No
Drug product claim
No
Assignee
Zhejiang Tongyuankang Medicine Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.